US 12,459,997 B2
Compounds and methods targeting interleukin-19
Richard Earl Higgs, Jr., Zionsville, IN (US); Robert John Konrad, Carmel, IN (US); Brian Jeffrey Nickoloff, Carmel, IN (US); and Robert William Siegel, II, Fountaintown, IN (US)
Assigned to Eli Lilly and Company, Indianapolis, IN (US)
Filed by Eli Lilly and Company, Indianapolis, IN (US)
Filed on Jan. 25, 2023, as Appl. No. 18/159,393.
Application 18/159,393 is a division of application No. 16/903,731, filed on Jun. 17, 2020, granted, now 11,591,387.
Application 16/903,731 is a continuation of application No. PCT/US2019/013565, filed on Jan. 15, 2019.
Claims priority of provisional application 62/618,200, filed on Jan. 17, 2018.
Prior Publication US 2023/0220062 A1, Jul. 13, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/24 (2006.01)
CPC C07K 16/244 (2013.01) [C07K 2317/34 (2013.01); C07K 2317/565 (2013.01)] 2 Claims
 
1. A method of detecting IL-19 in a patient sample comprising the steps of:
contacting the patient sample with a first antibody, said first antibody binding a first epitope region of IL-19;
wherein the first antibody comprises a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein the LCR and HCVR are selected from:
a. the LCVR having the amino acid sequence of SEQ ID NO: 66 and the HCVR having the amino acid sequence of SEQ ID NO: 70;
b. the LCVR having the amino acid sequence of SEQ ID NO: 74 and the HCVR having the amino acid sequence of SEQ ID NO: 78;
c. the LCVR having the amino acid sequence of SEQ ID NO: 82 and the HCVR having the amino acid sequence of SEQ ID NO: 86;
d. the LCVR having the amino acid sequence of SEQ ID NO: 34 and the HCVR having the amino acid sequence of SEQ ID NO: 38;
e. the LCVR having the amino acid sequence of SEQ ID NO: 42 and the HCVR having the amino acid sequence of SEQ ID NO: 46;
f. the LCVR having the amino acid sequence of SEQ ID NO: 50 and the HCVR having the amino acid sequence of SEQ ID NO: 54;
g. the LCVR having the amino acid sequence of SEQ ID NO: 58 and the HCVR having the amino acid sequence of SEQ ID NO: 62;
h. the LCVR having the amino acid sequence of SEQ ID NO: 294 and the HCVR having the amino acid sequence of SEQ ID NO: 298; and
i. the LCVR having the amino acid sequence of SEQ ID NO: 302 and the HCVR having the amino acid sequence of SEQ ID NO: 306, and
contacting the patient sample with a second antibody, said second antibody binding a second epitope region of IL-19 and said second antibody comprising a detectable label;
wherein the second antibody comprises a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein the LCVR comprises complementarity determining regions (CDRs) LCDR1 set forth in SEQ ID NO. 11, LCDR2 set forth in SEQ ID NO. 12, and LCDR3 set forth in SEQ ID NO. 13 and the HCVR comprises CDRs HCDR1 set forth in SEQ ID NO. 15, HCDR2 set forth in SEQ ID NO. 16 and HCDR3 set forth in SEQ ID NO. 17, and
detecting a signal provided by said detectable label of the second antibody contacting the patient sample.